Relay Therapeutics to Participate in Fireside Chat at the Cowen 2nd Annual Oncology Innovation Summit
Relay Therapeutics (Nasdaq: RLAY) will participate in a fireside chat at the Cowen 2nd Annual Virtual Oncology Innovation Summit on May 20, 2021, at 11:20 AM ET.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Relay Therapeutics (Nasdaq: RLAY) will participate in a fireside chat at the Cowen 2nd Annual Virtual Oncology Innovation Summit on May 20, 2021, at 11:20 AM ET. The event will be webcast live and accessible via the Investor page of Relay's website. A replay of the chat will be available for 90 days post-event, until August 18, 2021. Relay Therapeutics focuses on precision medicine, using its Dynamo™ platform to enhance drug discovery for challenging protein targets, particularly in oncology and genetic diseases.
Details
News Market Reaction – RLAY
The recorded move for RLAY in the trading session of this news was +6.15%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
CAMBRIDGE, Mass., May 14, 2021 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY) is scheduled to participate in a fireside chat at the Cowen 2nd Annual Virtual Oncology Innovation Summit on Thursday May 20, 2021 at 11:20am ET. The fireside chat will be webcast live and may be accessed from the Investor page of Relay’s website under Events and Presentations. Within 24 hours following the fireside chat, an archived replay of the webcast will be available until August 18, 2021.
About Relay Therapeutics
Relay Therapeutics (Nasdaq: RLAY) is a clinical-stage precision medicines company transforming the drug discovery process with the goal of bringing life-changing therapies to patients. Relay Therapeutics is the first of a new breed of biotech created at the intersection of disparate disciplines. The company’s Dynamo™ platform integrates an array of leading-edge computational and experimental approaches to effectively drug protein targets that have previously been intractable. The initial focus is on enhancing small molecule therapeutic discovery in targeted oncology and genetic disease. For more information, please visit www.relaytx.com or follow us on Twitter.
Contact:
Pete Rahmer
Senior Vice President, Corporate Affairs and Investor Relations
617-322-0715
prahmer@relaytx.com
Media:
Dan Budwick
1AB
973-271-6085
dan@1abmedia.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.